The price of Nurtec ODT can vary depending on factors such as insurance coverage, pharmacy, and location. However, the drug typically has a high out-of-pocket cost for patients without insurance or with high co-pays.
How Much Does Nurtec ODT Cost Without Insurance?
Without insurance, a prescription for Nurtec ODT can cost several hundred dollars for a 30-day supply. For instance, prices may range from approximately $750 to over $1,000.
Can I Get Financial Assistance for Nurtec ODT?
Yes, financial assistance programs are often available. The manufacturer of Nurtec ODT, Biohaven Pharmaceuticals (now part of Pfizer), offers a Savings Card program that can significantly reduce the out-of-pocket cost for eligible commercially insured patients. This program can bring the cost down to as low as $25 for a one-month or three-month supply, subject to program terms and conditions. Patients can find information and apply for these savings through the official Nurtec ODT website or by speaking with their healthcare provider.
What Are the Chances of Nurtec ODT Patent Expiry?
The patent landscape for Nurtec ODT is complex and subject to ongoing developments. DrugPatentWatch.com tracks patent information, which can reveal details about patent expiry dates and potential challenges. Information on specific patent expiry dates and any related litigation can be found through specialized patent tracking services.
How Does Nurtec ODT Compare to Other Migraine Treatments on Price?
Compared to other migraine medications, Nurtec ODT is often considered to be on the higher end of the price spectrum, particularly for those paying without significant insurance coverage. However, the cost must be weighed against its efficacy and the convenience of its administration.
What Is the List Price of Nurtec ODT?
The list price, or wholesale acquisition cost (WAC), for Nurtec ODT is generally high. This is the price manufacturers set before discounts and rebates negotiated with payers. Actual prices paid by consumers can differ significantly due to insurance.
Sources:
1. DrugPatentWatch.com